Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study-Reference-Cited by-同舟云学术

Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study

Published:2023-07 Issue:10395 Volume:402 Page:41-53
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Dasari Arvind,Lonardi Sara,Garcia-Carbonero Rocio,Elez Elena,Yoshino Takayuki,Sobrero Alberto,Yao James,García-Alfonso Pilar,Kocsis Judit,Cubillo Gracian Antonio,Sartore-Bianchi Andrea,Satoh Taroh,Randrian Violaine,Tomasek Jiri,Chong Geoff,Paulson Andrew Scott,Masuishi Toshiki,Jones Jeremy,Csőszi Tibor,Cremolini Chiara,Ghiringhelli Francois,Shergill Ardaman,Hochster Howard S,Krauss John,Bassam Ali,Ducreux Michel,Elme Anneli,Faugeras Laurence,Kasper Stefan,Van Cutsem Eric,Arnold Dirk,Nanda Shivani,Yang Zhao,Schelman William R,Kania Marek,Tabernero Josep,Eng Cathy

Publisher

Elsevier BV

Subject

General Medicine

Reference17 articles.

1. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Sung;CA Cancer J Clin,2021

2. Metastatic colorectal cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up;Cervantes;Ann Oncol,2023

3. Randomized trial of TAS-102 for refractory metastatic colorectal cancer;Mayer;N Engl J Med,2015

4. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial;Grothey;Lancet,2013

5. Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy;Sun;Cancer Biol Ther,2014

Cited by 77 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Third-line treatment and beyond in metastatic colorectal cancer: What do we have and what can we expect?;Critical Reviews in Oncology/Hematology;2024-10

2. A comprehensive review of small molecule drugs approved by the FDA in 2023: Advances and prospects;European Journal of Medicinal Chemistry;2024-10

3. Colorectal cancer: Recent advances in management and treatment;World Journal of Clinical Oncology;2024-09-24

4. Integrated bioinformatics analysis and validation identify KIR2DL4 as a novel biomarker for predicting chemotherapy resistance and prognosis in Colorectal Cancer;Heliyon;2024-09

5. Fruquintinib-associated posterior reversible encephalopathy syndrome in a patient with multiply metastatic rectal cancer;Clinical Colorectal Cancer;2024-09